US device industry calls for delay in controversial Diagnosis related groups reform
This article was originally published in Clinica
AdvaMed and four US medical groups have urged Medicare to wait a year before it acts on the most significant revision to its hospital payment rules in two decades. "The proposed rule in its current form is too much, too soon and too flawed," AdvaMed president Stephen Ubl said at a Washington press conference.
You may also be interested in...
Celltrion has announced plans to add a third biopharmaceutical facility and a new global biotechnology research center at the Korean firm’s existing site in Songdo, Incheon, as the firm also revealed record third-quarter financial results.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.